These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20198408)

  • 1. Bitter melon: antagonist to cancer.
    Nerurkar P; Ray RB
    Pharm Res; 2010 Jun; 27(6):1049-53. PubMed ID: 20198408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
    Raina K; Kumar D; Agarwal R
    Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bitter melon: a panacea for inflammation and cancer.
    Dandawate PR; Subramaniam D; Padhye SB; Anant S
    Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
    Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
    Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bitter Melon (
    Sur S; Ray RB
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
    Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
    Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Antitumor Activities of the Bitter Melon (Momordica charantia).
    Fang EF; Froetscher L; Scheibye-Knudsen M; Bohr VA; Wong JH; Ng TB
    Curr Protein Pept Sci; 2019; 20(3):296-301. PubMed ID: 29932035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse roles of bitter melon (
    Sur S; Ray RB
    J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34765739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bitter melon (Momordica charantia): a review of efficacy and safety.
    Basch E; Gabardi S; Ulbricht C
    Am J Health Syst Pharm; 2003 Feb; 60(4):356-9. PubMed ID: 12625217
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Bortolotti M; Mercatelli D; Polito L
    Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
    Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
    Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.
    Ru P; Steele R; Nerurkar PV; Phillips N; Ray RB
    Cancer Prev Res (Phila); 2011 Dec; 4(12):2122-30. PubMed ID: 21911444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management.
    Snee LS; Nerurkar VR; Dooley DA; Efird JT; Shovic AC; Nerurkar PV
    Nutr J; 2011 Jul; 10():78. PubMed ID: 21794176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermal treatment enhances the α-glucosidase inhibitory activity of bitter melon (Momordica charantia) by increasing the free form of phenolic compounds and the contents of Maillard reaction products.
    Hsieh HJ; Lin JA; Chen KT; Cheng KC; Hsieh CW
    J Food Sci; 2021 Jul; 86(7):3109-3121. PubMed ID: 34146408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Pre-clinical Efficacy of Chinese and Indian Cultivars of Bitter Melon (
    Kandhari K; Paudel S; Raina K; Agarwal C; Kant R; Wempe MF; O'Bryant C; Agarwal R
    J Cancer Prev; 2021 Dec; 26(4):266-276. PubMed ID: 35047453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
    Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
    Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
    Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
    Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats.
    Shih CC; Lin CH; Lin WL; Wu JB
    J Ethnopharmacol; 2009 May; 123(1):82-90. PubMed ID: 19429344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolite profiling and in vitro biological activities of two commercial bitter melon (Momordica charantia Linn.) cultivars.
    Perez JL; Jayaprakasha GK; Patil BS
    Food Chem; 2019 Aug; 288():178-186. PubMed ID: 30902279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bitter melon (Momordica charantia l.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice.
    Nagasawa H; Watanabe K; Inatomi H
    Am J Chin Med; 2002; 30(2-3):195-205. PubMed ID: 12230008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.